Poly (ADP-ribose) Polymerase (PARP) has a well-established function in DNA restore processes, and small molecule inhibitors of PARP have been developed as chemotherapy sensitisers for the therapy of most cancers. The following demonstration that PARP inhibition is selective for BRCA1 Read more…
Whereas target-specific medication can be found for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailor-made remedy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary carcinomas. Triple-negative tumors account for 15% of all breast cancers and often harbor defects in Read more…